The primary objective of this trial is to determine if perioperative risk stratification and risk-based, protocol-driven management leads to a reduction in the rate of death or serious complications compared to standard perioperative management in patients undergoing elective major cancer surgery.
Major cancer surgery is associated with significant rates of postoperative mortality and major morbidity. Postoperative morbidity adversely impacts healthcare utilization, healthcare costs, rates of discharge to home, quality of life, rates of receipt of postoperative anti-neoplastic therapy, disease-free survival, and overall survival. The investigators hypothesize that perioperative risk stratification and risk-based, protocol-driven management (compared to standard perioperative management) will lead to a reduction in 30-day post-operative mortality or major morbidity in patients undergoing major cancer surgery. This is based on our theory that preoperative/postoperative use of newly developed, perioperative risk-prediction tools will help identify patients at increased risk of postoperative death or serious complications that might benefit from risk-based, protocol-driven perioperative management, including escalating levels of care, escalating levels of monitoring, and escalating levels of hospitalist co-management. The set of assessments and interventions in the proposed study are conceptually similar to other "bundled" interventions which have recently been recently tested and demonstrated to reduce perioperative mortality and morbidity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,456
Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
Postoperative risk-prediction tool based on intraoperative variables
Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Rate of death or serious complications (as defined by American College of Surgeons National Surgical Quality Improvement Program [ACS NSQIP])
Time frame: 30-day postoperative period
Rate of death
Time frame: 30-day postoperative period
Rate of serious complication (as defined by ACS NSQIP)
Time frame: 30-day postoperative period
Rate of serious/grade 3-4 adverse event (as defined by CTCAE)
Time frame: 30-day postoperative period
Rate of Clavien-Dindo grade IIIa-V complication (as defined by ACS NSQIP)
Time frame: 30-day postoperative period
Rate of Clavien-Dindo grade IIIa-V adverse event (as defined by CTCAE)
Time frame: 30-day postoperative period
Rate of cardiac complications
Time frame: 30-day postoperative period
Rate of pulmonary complications
Time frame: 30-day postoperative period
Rate of renal complications
Time frame: 30-day postoperative period
Rate of wound complications
Time frame: 30-day postoperative period
Rate of infectious complications
Time frame: 30-day postoperative period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
Varying use of Hospitalist co-management
Routine postoperative care, as medically indicated
Rate of return to the operating room
Time frame: 30-day postoperative period
Rate of primary intensive care unit admission
Time frame: From date of index surgery to date of hospital discharge, up to 3 months
Rate of secondary intensive care unit admission
Time frame: From date of index surgery to date of hospital discharge, up to 3 months
Length of stay
Time frame: From date of index surgery to date of hospital discharge, up to 3 months
Total hospital charges
Time frame: From date of index surgery to date of hospital discharge, up to 3 months
Rate of discharge to home
Time frame: From date of index surgery to date of hospital discharge, up to 3 months
Rate of hospital readmission
Time frame: 30-day postoperative period
Health-related quality of life
Time frame: Postoperative (at 30 days)
Receipt of anti-neoplastic therapy
Time frame: 30-day postoperative period
Overall survival
Time frame: From date of index surgery to date of death, loss to follow-up, or end of study, whichever comes first, assessed up to 60 months